US 11,944,634 B2
Tetracycline compositions
David C. Griffith, San Marcos, CA (US); Serge Boyer, San Diego, CA (US); Scott Hecker, Del Mar, CA (US); and Michael N. Dudley, San Diego, CA (US)
Assigned to MELINTA SUBSIDIARY CORP., Morristown, NJ (US)
Filed by Melinta Subsidiary Corp., Morristown, NJ (US)
Filed on Feb. 27, 2019, as Appl. No. 16/287,639.
Application 16/287,639 is a continuation of application No. 15/660,698, filed on Jul. 26, 2017, abandoned.
Application 15/660,698 is a continuation of application No. 14/562,449, filed on Dec. 5, 2014, granted, now 9,744,179, issued on Aug. 29, 2017.
Application 14/562,449 is a continuation of application No. 13/654,018, filed on Oct. 17, 2012, granted, now 9,278,105, issued on Mar. 8, 2016.
Application 13/654,018 is a continuation of application No. PCT/US2011/036351, filed on May 12, 2011.
Claims priority of provisional application 61/392,304, filed on Oct. 12, 2010.
Claims priority of provisional application 61/334,106, filed on May 12, 2010.
Prior Publication US 2020/0000828 A1, Jan. 2, 2020
Int. Cl. A61K 9/19 (2006.01); A61K 9/00 (2006.01); A61K 31/65 (2006.01); A61K 47/02 (2006.01)
CPC A61K 31/65 (2013.01) [A61K 9/0019 (2013.01); A61K 47/02 (2013.01)] 25 Claims
 
1. An intravenous formulation comprising:
an aqueous solution of a single antibiotic ingredient and a magnesium cation;
wherein:
the single antibiotic ingredient is minocycline;
the molar ratio of the magnesium cation to the minocycline is greater than 4:1;
the formulation has a pH greater than 4 and less than 7; and
administration of the intravenous formulation results in reduced injection site hemolysis relative to intravenous administration of a control intravenous formulation that does not include magnesium.